Dexmedetomidine and Subarachnoid Haemorrhage

Turku University Hospital (TYKS)

Status and phase: Completed; Phase 2; Phase 1

Conditions: Subarachnoid Hemorrhage; Aneurysm

Treatments: Drug: Dexmedetomidine infusion

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01664520

KLNRO 45/2012 (Other Identifier)

Turku University Hospital

2012-000068-11 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to investigate how dexmedetomidine affects static and dynamic autoregulation, intracranial pressure (ICP) and cerebral oxygenation in aneurysmal subarachnoid haemorrhage (SAH) patients.

Full description

Dexmedetomidine is a selective α2-agonist which induces sedation, anxiolysis and analgesia without respiratory depression. These effects, as well as neuroprotective properties in experimental studies would be ideal in neuroanaesthesia and in neurocritical care. Poor grade SAH patients are treated in intensive care units (ICU). These patients are sedated often with propofol. However, to assess the patient's neurology, the propofol sedation must be stopped and the wakening of the patient may take time. Dexmedetomidine would be more advantageous, allowing wakening during the infusion. However, the effects of dexmedetomidine on cerebral autoregulation are unknown in SAH patients.

15 SAH patients requiring sedation, mechanical ventilation and ICP monitoring will be rolled in to the study.

Enrollment: 10 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aneurysmal SAH
• Aneurysm treated with coil(s) or clip(s)
• Age 18-80 years
• Written informed consent from the next of kin

Exclusion criteria

• Pregnancy
• Nursing woman
• Sick sinus syndrome
• Carotid stenosis
• Heart rate less than 50 beats / minute
• Mean arterial pressure less than 50 mmHg

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Dexmedetomine infusion

Experimental group

Treatment:

Drug: Dexmedetomidine infusion